Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT06325488

Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease

Led by Caroline Michaela Kistorp · Updated on 2025-04-06

60

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

C

Caroline Michaela Kistorp

Lead Sponsor

S

Sanofi

Collaborating Sponsor

AI-Summary

What this Trial Is About

The overall objective of this study is to investigate Fabry-associated renal organ involvement by using a novel magnetic resonance imaging (MRI) approach, focusing on changes in renal oxygen levels by blood oxygenation-level dependent (BOLD) imaging. Furthermore, to correlate renal oxygenation to the phenotypic presentation of patients with Fabry-associated nephropathy regarding circulating and imaging-derived biomarkers of kidney inflammation, fibrosis and injury as compared with healthy age- and sex-matched controls. The study will achieve this by: 1\) Using a non-invasive, contrast-free MRI protocol focusing on parameters of oxygenation, inflammation, fibrosis, and injury in the kidney. 2\) Using an extensive, in-depth biomarker blood panel to investigate the pathological pathways associated with Fabry disease and Fabry-associated nephropathy.

CONDITIONS

Official Title

Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female individuals 18 years of age or older
  • Able to give informed consent
Not Eligible

You will not qualify if you...

  • Any contraindication for magnetic resonance imaging, including claustrophobia, metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup/tattoos not declared MR compatible
  • Pregnancy
  • For control group: genetically verified Fabry disease or family member with Fabry disease
  • Cancer expected to influence life expectancy
  • Known heart failure, previous stroke, or established kidney disease
  • Initiation or change of antihypertensive therapy within 3 months before enrollment
  • Renal impairment classified as CKD G2/A1 or worse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Rigshospitalet

Copenhagen, Denmark, 2100

Actively Recruiting

Loading map...

Research Team

C

Caroline M Kistorp, Professor

CONTACT

N

Niels H Brandt-Jacobsen, MD, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here